Project Grant F31CA294908
Award Date
12/17/24
Completion Date
7/31/28
Dollars Obligated
$108K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This $1,130,538 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to target the tumor-specific Tn antigen in pancreatic ductal adenocarcinoma (PDAC). The University of Louisville, as the prime awardee, will: Determine how the Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins using mouse models and clinical specimens. Validate the role of natural killer cells in the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $627,272 to The Johns Hopkins University to optimize the efficacy of chimeric antigen receptor (CAR) T cells against pancreatic tumors. The researchers will engineer synthetic cytokine receptors (called "Velocity Receptors") on the CAR T cells to enhance their migration speed and tumor infiltration. They will test the motility and cell-killing capability of these engineered...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $138,742 to The Johns Hopkins University to investigate immunotherapy-induced alterations to cellular communication networks in pancreatic ductal adenocarcinoma (PDAC). The key research objectives are to: 1) develop statistical methods to identify cellular interactions that differ between immunotherapy treatment groups in single-cell RNA sequencing data from PDAC clinical trials, and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $356,732 to The Medical College of Wisconsin, Inc. to investigate the role of CCR6 in pancreatic cancer and regulatory T cells (Tregs). The central hypothesis is that CCL20-induced "super suppressor" CCR6+ Tregs mediate immunosuppression in the pancreatic cancer tumor microenvironment. The project aims to characterize this CCR6+ Treg population, assess the impact of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will support research to gain a comprehensive understanding of how adoptive T cell therapy (ACT) becomes dysfunctional within the tumor microenvironment of pancreatic cancer. The $169,344 award, running from 09/01/2024 to 08/31/2026, will leverage single-cell and spatial multi-omics analyses, computational modeling, and functional experiments to: 1) identify targetable T...
This federal Project Grant award, with ID R21CA299593, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The USD 269,280 award to the Translational Genomics Research Institute (TGen) aims to determine the biological effects of a senescent cell targeted antibody, SIWA318, and evaluate its potential to improve the efficacy of standard-of-care chemotherapy or immune checkpoint inhibitors in preclinical models for pancreatic ductal...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research program) provides $537,985 to the University of Texas MD Anderson Cancer Center to deeply characterize the location, distribution, and spatial functionality of microbes within the tumor microenvironment of primary pancreatic ductal adenocarcinoma (PDAC) tumors, as well as their influence on tumor growth, pre-metastatic niche formation, and liver metastasis. The research will utilize...
This Project Grant award, totaling $103,948, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The funding supports research to investigate the role of the Ran guanine exchange factor, RCC1, in driving the progression of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer. The research aims to use state-of-the-art transcriptomics and metabolomics approaches to elucidate how...